Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

200410,934 citationsJournal Articlebronze Open Access

Authors

Herbert I. Hurwitz · Duke University

Louis Fehrenbacher

William Novotny

Thomas H. Cartwright

John D. Hainsworth · Sarah Cannon

W. Heim

Jordan Berlin · Vanderbilt University

Ari David Baron · California Pacific Medical Center

S. Griffing

Abstract

The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 350, Issue 23, pp. 2335-2342

DOI: 10.1056/nejmoa032691

Field-Weighted Citation Impact: 332.80